Introduction
Medium-chain acyl-CoA dehydrogenase (MeAD) deficiency is a relatively common inherited metabolic defect causing liver dysfunction and hypoglycaemic coma and accounting for some of the cases of sudden death in infants [1,7.] . The mutation responsible for MCAD deficiency in five families is a point mutation causing a lysine to glutamic acid change at position 304 of the mature protein. According to the three-dimensional structure, Lys-304 is not part of the active site but is part of the helix which forms the interface between the subunits [3] . In this report we demonstrate expression of mutant MCAD-glu-304 in E.coli and biochemical characterization of the defective enzyme in comparison with wild-type MCAD. 
Results
Construction of plasmids: We have described the construction of a plasrr.id (pWTMCAD-Z). which directs expression of mature human MCAD in E.coli [4) . A derivative of pW1MCAD-2, pBMCK2-, which expresses mature active human MCAD under control of the lac promoter, was constructed ( fig. 1) . The EcoRI/BamHI fragment of pBMCKZ carrying the information for the C-terminal half of MCAD was replaced with an EcoRI/BamHI fragment originating from a PCR clone with the glu-304 mutation ( fig.I ). The plasmid encompassing the sequence of MCAD-glu-304 was called p985-4l. In order to ensure that no PCR errors are contained, the whole EcoRI/BamHI fragment was sequenced and found to be identical to the wild-type sequence with the exception of the lys to glu codon change.
Expression of wild-type and qlu-304 mutant MeAD in E.coli: Both plasmids, pBMCK2-(wild-type) and p985-4l (glu-304 mutant). express correctly-sized. immunoreactive MCAD protein ( fig.2) . In comparison between wild-type and lys 304, cells disrupted by boiling in electrophoresis sample buffer display additional and more pronounced degradation bands for the mutant. In extracts prepared by lysozyme disruption of the cells, the band for the mutant protein is much weaker than that of the wild-type. This indicates that after disruption the mutant protein is more susceptible to proteolytic degradation than the wild-type.
Activity in extracts: Extracts of cells expressing wild type or glu-304 MCAD respectively were assayed for enzyme activity. Extracts were prepared by lysozyme disruption followed by NH4-sulfate precipitation (20-70%) and activity was measured as described by Thorpe MCAD activity in the fractions containing MCAD-gIu-J04 detected by western blotting was measured as described above. No MCAD activity was found. From the estimation of the amount of MeAD-glu-304 present in the assay, it should be sufficient to warrant detection of activity. This indicates that the mutant protein is inactive or at least has decreased activity.
Conclusions
Our results strongly suggest that the lys to glu mutation in MCAD found in patients with MCAD deficiency renders the protein highly susceptible toward proteolytic degradation. This is probably the reason for lack of activity. Whether the mutant protein has some intrinsic activity cannot be conclusively excluded since the amount of purified enzyme is very low and estimation of the concentration is not sufficiently reliable with our assay system. The fact that MCAD-glu-304 elutes from the hydroxylapatite column at various salt concentrations may imply that different forms of the protein are present. Whether this reflects different tertiary and/or quarternary structure remains to be determined.
